Bridgebio Pharma Stock Performance
| BBIO Stock | USD 23.42 0.18 0.77% |
The firm shows a Beta (market volatility) of 0.94, which signifies possible diversification benefits within a given portfolio. BridgeBio Pharma returns are very sensitive to returns on the market. As the market goes up or down, BridgeBio Pharma is expected to follow. At this point, BridgeBio Pharma has a negative expected return of -0.0986%. Please make sure to confirm BridgeBio Pharma's skewness, and the relationship between the treynor ratio and rate of daily change , to decide if BridgeBio Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BridgeBio Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, BridgeBio Pharma is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.77 | Five Day Return 0.43 | Year To Date Return (42.10) | Ten Year Return (14.99) | All Time Return (14.99) |
1 | BRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General Kahn Swick Foti, LLC Investigates BridgeBio Pharma, Inc. - BBIO | 08/30/2024 |
2 | BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42 percent Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality a... | 09/27/2024 |
3 | Disposition of 28148 shares by Neil Kumar of BridgeBio Pharma at 24.4 subject to Rule 16b-3 | 10/17/2024 |
4 | BridgeBio Shares Positive Data from High Dose Cohort of Phase 12 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 | 10/24/2024 |
5 | BridgeBio Pharma Expected to Beat Earnings Estimates What to Know Ahead of Q3 Release | 10/31/2024 |
6 | Amphastar Pharmaceuticals Lags Q3 Earnings and Revenue Estimates | 11/06/2024 |
7 | Prosight Management, LP Reduces Stake in Vincerx Pharma Inc | 11/13/2024 |
8 | BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL ... | 11/18/2024 |
9 | BridgeBio Pharmas Acoramidis Shows Competitive Edge Against Pfizers Tafamidisa In Lucrative But Competitive ATTR-CM Market | 11/19/2024 |
10 | Why Is BridgeBio Pharma, Inc. Among the Worst Performing Biotech Stocks in 2024 | 11/21/2024 |
11 | Disposition of 6704 shares by Stephenson Brian C of BridgeBio Pharma subject to Rule 16b-3 | 11/22/2024 |
| Begin Period Cash Flow | 416.9 M |
BridgeBio |
BridgeBio Pharma Relative Risk vs. Return Landscape
If you would invest 2,590 in BridgeBio Pharma on August 26, 2024 and sell it today you would lose (248.00) from holding BridgeBio Pharma or give up 9.58% of portfolio value over 90 days. BridgeBio Pharma is currently does not generate positive expected returns and assumes 3.414% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than BridgeBio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BridgeBio Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BridgeBio Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BridgeBio Pharma, and traders can use it to determine the average amount a BridgeBio Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0289
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BBIO |
Estimated Market Risk
| 3.41 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BridgeBio Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BridgeBio Pharma by adding BridgeBio Pharma to a well-diversified portfolio.
BridgeBio Pharma Fundamentals Growth
BridgeBio Stock prices reflect investors' perceptions of the future prospects and financial health of BridgeBio Pharma, and BridgeBio Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BridgeBio Stock performance.
| Return On Equity | -17.9 | ||||
| Return On Asset | -0.49 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (68.50) % | ||||
| Current Valuation | 5.86 B | ||||
| Shares Outstanding | 188.99 M | ||||
| Price To Earning | (13.72) X | ||||
| Price To Book | 123.68 X | ||||
| Price To Sales | 20.33 X | ||||
| Revenue | 9.3 M | ||||
| Gross Profit | 74.21 M | ||||
| EBITDA | (565.47 M) | ||||
| Net Income | (653.25 M) | ||||
| Cash And Equivalents | 715.71 M | ||||
| Cash Per Share | 4.83 X | ||||
| Total Debt | 1.74 B | ||||
| Debt To Equity | 4.61 % | ||||
| Current Ratio | 5.46 X | ||||
| Book Value Per Share | (6.51) X | ||||
| Cash Flow From Operations | (527.72 M) | ||||
| Earnings Per Share | (2.42) X | ||||
| Market Capitalization | 4.43 B | ||||
| Total Asset | 546.38 M | ||||
| Retained Earnings | (2.56 B) | ||||
| Working Capital | 333.75 M | ||||
| Current Asset | 513.67 M | ||||
| Current Liabilities | 51.37 M | ||||
About BridgeBio Pharma Performance
By examining BridgeBio Pharma's fundamental ratios, stakeholders can obtain critical insights into BridgeBio Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that BridgeBio Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 3.6 K | 3.8 K | |
| Return On Tangible Assets | (1.24) | (1.30) | |
| Return On Capital Employed | (1.51) | (1.58) | |
| Return On Assets | (1.18) | (1.24) | |
| Return On Equity | 0.47 | 0.50 |
Things to note about BridgeBio Pharma performance evaluation
Checking the ongoing alerts about BridgeBio Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BridgeBio Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BridgeBio Pharma generated a negative expected return over the last 90 days | |
| BridgeBio Pharma has high historical volatility and very poor performance | |
| BridgeBio Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 9.3 M. Net Loss for the year was (653.25 M) with profit before overhead, payroll, taxes, and interest of 74.21 M. | |
| BridgeBio Pharma currently holds about 715.71 M in cash with (527.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83. | |
| BridgeBio Pharma has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Why Is BridgeBio Pharma, Inc. Among the Worst Performing Biotech Stocks in 2024 |
- Analyzing BridgeBio Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BridgeBio Pharma's stock is overvalued or undervalued compared to its peers.
- Examining BridgeBio Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BridgeBio Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BridgeBio Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BridgeBio Pharma's stock. These opinions can provide insight into BridgeBio Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.